- Home
- CNET vs ZVSA Comparison
CNET vs ZVSA Comparison
Compare CNET & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNET
- ZVSA
- Stock Information
- Founded
- CNET 2003
- ZVSA 2014
- Country
- CNET Hong Kong
- ZVSA United States
- Employees
- CNET N/A
- ZVSA N/A
- Industry
- CNET Advertising
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- CNET Consumer Discretionary
- ZVSA Health Care
- Exchange
- CNET Nasdaq
- ZVSA Nasdaq
- Market Cap
- CNET 3.4M
- ZVSA 3.0M
- IPO Year
- CNET N/A
- ZVSA N/A
- Fundamental
- Price
- CNET $1.66
- ZVSA $0.55
- Analyst Decision
- CNET
- ZVSA
- Analyst Count
- CNET 0
- ZVSA 0
- Target Price
- CNET N/A
- ZVSA N/A
- AVG Volume (30 Days)
- CNET 59.2K
- ZVSA 11.7M
- Earning Date
- CNET 08-15-2025
- ZVSA 08-08-2025
- Dividend Yield
- CNET N/A
- ZVSA N/A
- EPS Growth
- CNET N/A
- ZVSA N/A
- EPS
- CNET N/A
- ZVSA N/A
- Revenue
- CNET $13,560,000.00
- ZVSA N/A
- Revenue This Year
- CNET N/A
- ZVSA N/A
- Revenue Next Year
- CNET N/A
- ZVSA N/A
- P/E Ratio
- CNET N/A
- ZVSA N/A
- Revenue Growth
- CNET N/A
- ZVSA N/A
- 52 Week Low
- CNET $1.11
- ZVSA $0.47
- 52 Week High
- CNET $4.53
- ZVSA $5.30
- Technical
- Relative Strength Index (RSI)
- CNET 58.88
- ZVSA 40.84
- Support Level
- CNET $1.42
- ZVSA $0.65
- Resistance Level
- CNET $1.84
- ZVSA $1.67
- Average True Range (ATR)
- CNET 0.12
- ZVSA 0.12
- MACD
- CNET 0.04
- ZVSA -0.02
- Stochastic Oscillator
- CNET 67.27
- ZVSA 1.63
About CNET ZW Data Action Technologies Inc.
ZW Data Action Technologies Inc is engaged in providing Internet advertising, precision marketing, e-commerce online to offline (O2O) advertising and marketing services as well as related data and technical services to small and medium enterprises in the PRC. It offers a variety channel of advertising and marketing services through its system, including distribution of the right to use search engine marketing services, provision of online advertising placements on its web portals, provision of e-commerce O2O advertising and marketing services, and provision of other related value-added data and technical services to maximize market exposure and effectiveness for clients.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.